Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine (COVID-19)
A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia
Sponsor: Faculty of Medicine Universitas Padjadjaran
Listed as NCT04508075, this PHASE3 trial focuses on SARS-CoV2 Infection and remains completed. Sponsored by Faculty of Medicine Universitas Padjadjaran, it has been updated 7 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Feb 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Faculty of Medicine Universitas Padjadjaran
- National Intitute of Health Research and Development, Ministry of Health Republic of Indonesia
- PT Bio Farma
- Sinovac Life Sciences Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .